News | March 09, 2021
NATCO receives approval for Everolimus tablets for the US market
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
ranules now has a total of 38 ANDA approvals from US FDA.
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
The centralized marketing authorization granted by the EC is valid in all EU Member
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
Subscribe To Our Newsletter & Stay Updated
